

Clinical features associated with *Pseudomonas aeruginosa* colonization in children under 2 years of age: a retrospective study of Cystic Fibrosis Registry

Ece Ocak¹, Güzin Cinel¹, Gökçen Dilşa Tuğcu¹, Sanem Eryılmaz Polat¹,
Dilber Ademhan Tural², Beste Özsezen², Ebru Yalçın², Nural Kiper², Velat Şen³,
Hadice Selimoğlu Şen⁴, Derya Ufuk Altıntaş⁵, Ayşe Ayzıt Kılınç⁶, Haluk Çokuğraş⁶,
Hakan Yazan⁷, Gökçen Ünal⁸, Aslı İmran Yılmaz⁸, İlim Irmak⁹, Ebru Damadoğlu⁹,
Gökçen Kartal Öztürk¹⁰, Esen Demir¹⁰, Erdem Başaran¹¹, Ayşen Bingöl¹¹,
Nihat Sapan¹², Yakup Canitez¹², Pelin Asfuroğlu¹³, Ayşe Tana Aslan¹³,
Koray Harmancı¹⁴, Melih Hangül¹⁵, Mehmet Köse¹⁵, Ali Özdemir¹⁶, Gizem Özcan¹⁷,
Nazan Çobanoğlu¹⁷, Zeynep Gökçe Gayretli Aydın¹⁸, Özlem Keskin¹⁹, Hasan Yüksel²⁰,
Şebnem Özdoğan²¹, Erdem Topal²², Gönül Çaltepe²³, Demet Can²⁴, Pervin Korkmaz²⁵,
Mehmet Kılıç²⁶, Tuğba Şişmanlar Eyüboğlu¹³, Sevgi Pekcan⁸, Erkan Çakır²⁷,
Nagehan Emiralioğlu², Uğur Özçelik², Deniz Doğru²

¹Department of Pediatric Pulmonology, Ministry of Health Ankara City Hospital, Ankara, Türkiye; ²Department of Pediatric Pulmonology, Faculty of Medicine, Hacettepe University, Ankara, Türkiye; ³Department of Pediatric Pulmonology, Faculty of Medicine, Dicle University, Diyarbakır, Türkiye; ⁴Department of Chest Diseases, Faculty of Medicine, Dicle University, Diyarbakır, Türkiye; ⁵Department of Pediatric Allergy and Immunology, Faculty of Medicine, Çukurova University, Adana, Türkiye; ⁶Department of Pediatric Pulmonology, Cerrahpaşa Faculty of Medicine, İstanbul University-Cerrahpaşa, İstanbul, Türkiye; ⁷Department of Pediatric Pulmonology, Faculty of Medicine, Bezmialem Vakıf University, İstanbul, Türkiye; ⁸Department of Pediatric Pulmonology, Meram Medicine Faculty, Necmettin Erbakan University, Konya, Türkiye; ⁹Department of Chest Diseases, Faculty of Medicine, Hacettepe University, Ankara, Türkiye; ¹⁰Department of Pediatric Pulmonology, Faculty of Medicine, Ege University, İzmir, Türkiye; ¹¹Department of Pediatric Pulmonology, Faculty of Medicine, Akdeniz University, Antalya, Türkiye; ¹²Department of Pediatric Allergy and Immunology, Faculty of Medicine, Bursa Uludağ University, Bursa, Türkiye; ¹³Department of Pediatric Pulmonology, Faculty of Medicine, Gazi University, Ankara, Türkiye; ¹⁴Department of Pediatric Allergy and Immunology, Faculty of Medicine, Osmangazi University, Eskişehir, Türkiye; ¹⁵Department of Pediatric Pulmonology, Faculty of Medicine, Erciyes University, Kayseri, Türkiye; ¹⁶Department of Pediatric Pulmonology, Ministry of Health Mersin City Hospital, Mersin, Türkiye; ¹⁷Department of Pediatric Pulmonology, Faculty of Medicine, Ankara University, Ankara, Türkiye; ¹⁸Department of Pediatric Infectious Diseases, Faculty of Medicine, Karadeniz Technical University, Trabzon, Türkiye; ¹⁹Department of Pediatric Allergy and Immunology, Faculty of Medicine, Gaziantep University, Gaziantep, Türkiye; ²⁰Department of Pediatric Allergy and Immunology, Faculty of Medicine, Celal Bayar University, Manisa, Türkiye; ²¹Department of Pediatric Pulmonology, Şişli Hamidiye Etfal Research and Training Hospital, İstanbul, Türkiye; ²²Department of Pediatric Allergy, Faculty of Medicine, İnönü University, Malatya, Türkiye; ²³Department of Pediatric Gastroenterology, Hepatology and Nutrition, Faculty of Medicine, Ondokuz Mayıs University, Samsun, Türkiye; ²⁴Department of Pediatric Pulmonology, Faculty of Medicine, Balıkesir University, Balıkesir, Türkiye; ²⁵Department of Chest Diseases, Faculty of Medicine, Ege University, İzmir, Türkiye; ²⁶Department of Pediatric Pulmonology, Faculty of Medicine, Ege University, İzmir, Türkiye; ²⁷Department of Pediatric Pulmonology, Faculty of Medicine, İstinye University, İstanbul, Türkiye.

✉ Ece Ocak • ecesakizli@gmail.com

Received 1st Dec 2025, revised 5th Jan 2026, 13th Feb 2026, 9th Mar 2026, accepted 10th Mar 2026.

Our research has been presented in “Türk Toraks Derneği 24. Yıllık Kongresi, 2021” as an oral presentation and in “European Respiratory Society Congress, 2022” as a poster presentation.

Copyright © 2026 The Author(s). This is an open access article distributed under the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

ABSTRACT

Background. Respiratory colonization with *Pseudomonas aeruginosa* is associated with increased morbidity and mortality in cystic fibrosis (CF) patients. This study aims to assess the clinical characteristics and associated factors of CF infants under two years of age with *P. aeruginosa* colonization in Türkiye.

Method. Of the 1637 patients registered in the Cystic Fibrosis Registry of Türkiye in 2019, 284 patients under two years of age were included in this retrospective cross-sectional study. Patients were classified into two groups: those with *P. aeruginosa* colonization (Group 1) and those without (Group 2). Cystic fibrosis transmembrane conductance regulator (CFTR) gene functions were categorized according to CFTR mutation functional class.

Results. Twenty-three patients (8.1%) were categorized as Group 1 and 262 participants (91.9%) were classified as Group 2. Infants with *P. aeruginosa* colonization (Group 1) were more likely to have minimal CFTR function compared with those without colonization (87% vs. 39.8%, $p = 0.017$). In addition, both *Staphylococcus aureus* colonization (47.8% vs. 7.3%, $p < 0.001$) and methicillin-resistant *S. aureus* positivity (17.4% vs. 6.1%, $p = 0.042$) were observed more commonly in Group 1. There were no statistical differences between the groups in terms of age at diagnosis, gender, mean z-scores of weight and height, newborn screening test positivity, sweat chloride test results, and pancreatic insufficiency ($p > 0.05$). Univariate logistic regression analysis did not identify significant associated factors for *P. aeruginosa* colonization.

Conclusions. Our findings suggest that minimal CFTR function and *S. aureus* colonization are associated with *P. aeruginosa* colonization in CF patients under two years of age. Further studies are needed to investigate associated factors for early *P. aeruginosa* colonization, eradication treatment effectiveness, and longitudinal outcomes of in CF patients under two years of age.

Key words: Cystic fibrosis, *Pseudomonas aeruginosa*, colonization, children, registry.

Cystic fibrosis (CF) is the most common inherited disease in Caucasian populations caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes the ion channel-associated CFTR protein.¹ CFTR dysfunction leads to the colonization of an opportunistic Gram-negative pathogen, *Pseudomonas aeruginosa*.² Chronic infection with *P. aeruginosa* is one of the leading causes of morbidity and mortality in CF patients by contributing to progressive decline in pulmonary function.² With new modulator therapies, advances in supportive care, and enhanced treatment of respiratory infections and other complications, the predicted life expectancy of CF patients has increased to almost 50 years.³ Therefore, recognition and effective treatment of initial *P. aeruginosa* colonization is essential in maintaining lung health and long-life expectancy in children with CF.⁴

Longitudinal studies in children with CF assessed with bronchoscopy and oropharyngeal cultures have demonstrated a high prevalence

of *P. aeruginosa* in the first 2 years of life.⁵⁻⁸ Moreover, although chronic *P. aeruginosa* colonization is not commonly expected during the first years of life, very early acquisition in infancy represents a critical and vulnerable period, as initial airway colonization during this stage may have a disproportionate impact on subsequent disease severity and long-term outcomes, including mortality in young children with CF.^{7,9,10} However, the specific risk factors and clinical implications of *P. aeruginosa* colonization in infants remain inadequately understood, particularly in populations with genetic and environmental diversity. The fact that the prevalence of *P. aeruginosa* is not decreasing in our country, unlike in the United Kingdom, the United States, and European countries, makes the investigation of infant CF patients with *P. aeruginosa* colonization more important.¹¹⁻¹⁴

Based on our hypothesis that very early *P. aeruginosa* colonization during the first years of life represents a distinct and sensitive clinical entity, we specifically focused on infants under 2

years of age. In this retrospective cross-sectional study, we aimed to assess the clinical features of CF patients with *P. aeruginosa* colonization under 2 years of age, in order to evaluate the associated factors for *P. aeruginosa* colonization.

Methods

Study design

We conducted a retrospective cross-sectional study on children with CF aged under 2 years of age who had available data on *P. aeruginosa* colonization status in the Cystic Fibrosis Registry of Türkiye (CFRT) for 2019. Patients aged <2 years were divided into two groups: those with *P. aeruginosa* colonization (Group 1) and those without *P. aeruginosa* colonisation (Group 2). All analyses were compared with these two groups.

Data input to the registry was approved by the local ethics committee, and all patients and/or their parents signed written consent for the data entry. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Hacettepe University Ethics Board, date: 12 April 2007, reference number: HEK 07/16-21 and date: 5 June 2018, reference number: GO 18/473-31) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Diagnosis of *P. aeruginosa* colonization in cystic fibrosis

Cystic fibrosis diagnosis was established according to the European Cystic Fibrosis Society (ECFS) guideline.¹⁵ Chronic *P. aeruginosa* colonization was defined according to “modified Leeds criteria” as applied in the ECFSR guideline: > 50% of the samples (sputum/other) collected over a 12-month period should be positive; at least 4 samples collected.^{15,16} Samples were obtained at each outpatient clinic visit or during hospital stays

using cough swabs or oropharyngeal swabs, as the study population was unable to expectorate sputum, as reported in the literature.^{7,17} Infants are recommended to attend an outpatient clinic visits within the first 3 months of life after the diagnosis, then every 3-6 months until 2 years of age.¹⁸

Data variables

Age at the study period, age at diagnosis, gender, weight, height, z-scores of weight and height, history of meconium ileus, newborn screening test results, sweat chloride test results, medications, and results of *CFTR* genotype analysis were noted. As recommended by the CDC, Z-scores of weight and height measurements were assessed by using the World Health Organization growth charts for children < 24 months of age.^{19,20} CF patients with classic symptoms and signs of exocrine pancreatic insufficiency who also have fecal elastase values <200 µg/g are said to have pancreatic insufficiency.¹⁵

CFTR functions were categorized according to *CFTR* mutation functional class: minimal function (presence of only class I, II, or III mutations) and residual function (at least one class IV or V mutation).²¹⁻²³ Minimal function mutations are severe and commonly associated with advanced lung disease and pancreatic insufficiency, whereas residual function mutations are milder and linked to less severe clinical phenotypes.

The presence of microorganisms in respiratory cultures recorded during the 2019 registry year, such as *Staphylococcus aureus*, methicillin-resistant *S. aureus* (MRSA), and *Haemophilus influenzae*, *Stenotrophomonas maltophilia*, and *Achromobacter* species were noted. The colonization status of *P. aeruginosa*, *S. aureus*, and the *Burkholderia cepacia* complex were recorded. The data regarding associated complications, including pseudo-Bartter syndrome (PBS), CF-related liver disease, gastroesophageal reflux, sinusitis, pneumothorax, and hemoptysis, were also documented.

Statistical analysis

Statistical Package for the Social Sciences (SPSS for Windows Version 20) was used for statistical analyses. In the descriptive statistics section, categorical variables are presented with numbers, percentages, and continuous variables with mean $\pm$ standard deviation or median and interquartile range (IQR, Q1-Q3). The distribution of normality in groups was evaluated by Kolmogorov-Smirnov and Shapiro-Wilk tests. A comparison of the median values of two independent groups was measured by the Mann-Whitney U test. The percentage distribution of categorical data between groups was measured using the χ^2 test. Values of $p < 0.05$ were considered statistically

significant. Because of the limited number of outcome events, logistic regression analyses were restricted to univariate models.

Results

A total of 1637 patients were registered in the Cystic Fibrosis Registry of Türkiye in 2019. Among these, 284 (17.3%) patients under 2 years of age were included in this retrospective cross-sectional study.

In the study population ($n = 284$), 23 participants (8.1%) were assigned to group 1, while 262 participants (91.9%) were assigned to group 2. The eligibility assessment of patients included in the study is shown in Fig. 1.




Fig. 1. Flow chart of study population.

CF: cystic fibrosis.

Demographic and clinical characteristics

Demographic and clinical characteristics of the study population according to *P. aeruginosa* colonization status are shown in Table I. Since newborn screening for CF was introduced in Türkiye on January 1st, 2015, all patients had undergone newborn screening. Among those screened, 17 patients (73.9%) in Group 1 and 201 patients (77.0%) in Group 2 had a positive newborn screening result. There were no statistical differences between the groups in terms of age, age at diagnosis, gender, mean z-scores of weight and height, newborn screening test positivity, sweat chloride test results, and pancreatic insufficiency ($p > 0.05$).

CFTR genotype analysis

Genotype analysis was performed on all patients in Group 1 (Fig. 1). F508del homozygous and heterozygous mutations were present in one patient each. According to the CFTR functional classification, 20 (87%) patients had minimal CFTR function, and 1 (4.8%) had residual CFTR function.

In Group 2, at least one variant was detected in 201 of the 238 patients who were genotyped (Fig. 1). Nineteen patients (7.3%) were homozygous for the F508del mutation, and 38 (14.5%) were heterozygous for F508del. According to the CFTR functional classification, 84 patients (39.8%) had minimal CFTR function,

Table I. Comparison of demographic and clinical features of patients with cystic fibrosis under 2 years of age according to *P. aeruginosa* colonization.

Variables	Group 1	Group 2	p-value
	Patients with early <i>P. aeruginosa</i> colonization (n = 23)	Patients without early <i>P. aeruginosa</i> colonization (n = 262)	
Age at diagnosis, months, median (IQR)	2 (1-4)	2 (1-4)	0.659 ^a
Age*, months, median (IQR)	21 (11-24)	15 (9-24)	0.468 ^a
Gender, male, n (%)	12 (52.2)	132 (50.4)	0.869
Weight, kg, mean $\pm$ SD	10.1 $\pm$ 3.1	9.9 $\pm$ 3.0	0.743 ^b
Height, cm, mean $\pm$ SD	81.3 $\pm$ 10.0	78.3 $\pm$ 10.5	0.178 ^b
z-score for weight for age, mean $\pm$ SD	-1.43 $\pm$ 2.2	-1.2 $\pm$ 1.5	0.352 ^b
z-score for height, mean $\pm$ SD	-0.7 $\pm$ 1.4	-1.2 $\pm$ 1.6	0.860 ^b
Diagnosis by newborn screening, n (%)	17 (73.9)	201 (77)	0.144
History of meconium ileus, n (%)	0 (0.0)	15 (5.7)	0.238
Sweat chloride test, mmol/L, mean $\pm$ SD	71.5 $\pm$ 35.5	69.7 $\pm$ 22.9	0.717 ^b
Pancreatic insufficiency, n (%)	4 (17.3)	24 (9.1)	0.528
CFTR genotype analysis, done, n (%)	23 (100)	238 (90.8)	0.122
Homozygous F508del genotype, n (%)	1 (4.3)	18 (6.9)	0.641
Heterozygous F508del genotype, n (%)	1 (4.3)	38 (14.5)	0.178
CFTR classification, n (%)	n = 23	n = 211	
Minimal function	20 (87)	84 (39.8)	0.017
Residual function	1 (4.3)	35 (16.6)	
Unclassified	2 (8.7)	92 (43.6)	

*Age at the time of data entry for the 2019 registry year.

^aGroup comparisons were done using Mann-Whitney U test.

^bGroup comparisons were done using Student's t test

CFTR: cystic fibrosis transmembrane conductance regulator, IQR: interquartile range, SD: standard deviation.

and 35 (16.6%) had residual CFTR function. There was no statistical difference between the two groups regarding F508del homozygous and heterozygous mutations ($p > 0.05$). Patients in group 1 had a higher prevalence of minimal CFTR function than those in group 2 ($p = 0.017$).

Microbiological features

The prevalence of *S. aureus* (58.3% vs. 23.9%, $p = 0.007$) and MRSA (17.4% vs. 6.1%, $p = 0.042$)

on recent respiratory culture and *S. aureus* colonization (47.8% vs 7.3%, $p < 0.001$) were significantly higher in Group 1, compared with Group 2 (Table II).

Both *P. aeruginosa* and *S. aureus* colonization were present in five patients. In three cases, *S. aureus* colonization preceded *P. aeruginosa* colonization.

Table II. Treatments, microbiological results, and accompanying complications of the study cohort of cystic fibrosis patients under 2 years of age.

	Group 1 Patients with early <i>P. aeruginosa</i> colonization (n = 23), n (%)*	Group 2 Patients without early <i>P. aeruginosa</i> colonization (n = 262), n (%)*	p-value
Treatment			
DNase	23 (100)	217 (82.8)	0.030
Vitamin	21 (91.3)	196 (74.8)	0.073
Pancreatic enzymes	18 (78.3)	210 (80.2)	0.782
Inhaled hypertonic saline	3 (13)	10 (3.8)	0.042
Inhaled antibiotics	6 (26.1)	5 (1.9)	< 0.001
Oxygen therapy	2 (8.7)	2 (0.8)	0.034
Annual IV antibiotics days due to PEx, median (IQR)*	15.1 (0-59)	4.5 (0-70)	< 0.001^a
Microbiological findings**			
<i>Haemophilus influenzae</i>	1 (4.3)	26 (9.9)	0.708
<i>Staphylococcus aureus</i>	7 (58.3)	58 (23.9)	0.007
MRSA	4 (17.4)	16 (6.1)	0.042
<i>Stenotrophomonas maltophilia</i>	1 (4.3)	5 (1.9)	0.399
<i>Achromobacter</i>	0	2 (0.7)	0.674
Chronic colonization			
<i>Staphylococcus aureus</i>	11 (47.8)	19 (7.3)	< 0.001
<i>Burkholderia cepacia</i>	1 (4.3)	0	0.081
Complications			
Pseudo-Bartter syndrome	5 (21.7)	35 (13.4)	0.267
CF-related liver disease	2 (0.7)	21 (7.4)	0.442
Gastroesophageal reflux	1 (4.3)	16 (6.1)	0.901
Sinusitis	1 (4.3)	4 (1.5)	0.589

*Data given as number (percentage), except for annual IV antibiotic days due to PEx, presented as median (interquartile range).

**Presence of microorganisms in respiratory cultures during the 2019 registry year

^aGroup comparisons were done using Mann-Whitney U test.

CF: cystic fibrosis, IV: intravenous, MRSA: methicillin-resistant *Staphylococcus aureus*, PEx: pulmonary exacerbations

CF-related medical treatments and CF-related complications

Patients in Group 1 had statistically longer duration of antibiotic therapy for pulmonary exacerbations (15.1 vs. 4.5, $p < 0.001$), more oxygen therapy support (8.7% vs. 0.8%, $p = 0.034$), higher prevalence of DNase (100% vs. 82.7%, $p = 0.003$), inhaled hypertonic saline (13% vs. 3.8%, $p = 0.042$), and inhaled antibiotic treatments (26.1% vs. 1.9%, $p < 0.001$) than patients in Group 2. A comparison of the treatments, microbiological results, and accompanying complications of the groups is given in Table II.

There were no significant differences between the groups in terms of accompanying complications, including PBS, CF-related liver disease (elevated transaminases without cirrhosis), gastroesophageal reflux, and sinusitis ($p > 0.05$). No other complications were recorded in any patients (Table II). None of the patients in the study cohort were receiving CFTR modulator therapy during the study period.

In the univariate logistic regression analyses, no relationship was found between gender, age at diagnosis, newborn screening test positivity, sweat chloride test results, and pancreatic insufficiency on the probability of *P. aeruginosa* colonization.

Discussion

We described the characteristics of infants under 2 years of age with *P. aeruginosa* colonization in our country. The prevalence of *P. aeruginosa* colonization was found to be 8.1% under 2 years of age. *S. aureus* infection and colonization were significantly higher in patients with *P. aeruginosa* colonization. We demonstrated *P. aeruginosa* colonization was more frequent in infants with minimal CFTR function compared to those with residual CFTR function.

Age-specific data on *P. aeruginosa* colonization in early childhood are limited and inconsistently reported in annual registry summaries.^{13,15,24-27} For example, the prevalence of *P. aeruginosa* colonization has been reported as 2.1% in children under 3 years of age in the United Kingdom CF Registry and 6% in children under 4 years of age in the French CF Registry.^{13,27} In contrast, the overall prevalence of *P. aeruginosa* colonization across all pediatric age groups has been reported as approximately 3.3% in the UK and 20% in France. In this context, our study provides age-specific data for infants under 2 years of age and demonstrates a prevalence of chronic *P. aeruginosa* colonization of 8.1% in this early and vulnerable period, compared with an overall colonization rate of 20% reported in the national registry.²⁴

The age at initial *P. aeruginosa* acquisition is likely influenced by a complex interaction of bacterial, host-related (especially genetics), and environmental factors.^{4,28-30} Pulmonary microbial diversity—defined as the richness and relative abundance of different microorganisms within the airway—is highest in early childhood and has been shown to influence disease progression and susceptibility to early *P. aeruginosa* colonization in patients with CF.^{28,31} Moreover, studies have shown that increased airway inflammation, even in the absence of overt infection, may lead to early tissue damage and create a permissive environment for subsequent *P. aeruginosa* acquisition even in early infancy.^{4,32} These mechanisms may partly explain why early-life colonization occurs in a particularly vulnerable period of lung development.

In infants who do not expectorate sputum, respiratory surveillance commonly relies on oropharyngeal or cough swabs to identify *P. aeruginosa*.^{15,33} Although concerns remain about their diagnostic accuracy, a randomized controlled study demonstrated comparable clinical outcomes between bronchoalveolar lavage-guided and oropharyngeal culture-guided treatment strategies in young

children with CF.³⁴ Manos et al. showed that persistent *P. aeruginosa* strains in infants varied independently from isolation sites, such as upper or lower airways, and prior exposure of the airway to *P. aeruginosa*.³⁵ Taken together, these findings suggest that although the specific methods used for respiratory sample collection were not available in our study, the interpretation of our results remains reliable and consistent with existing evidence.

Patient characteristics such as lower socio-economic status, female gender, CFTR genotype, and microbial diversity in the lungs have been associated or identified as risk factors for the initial acquisition of *P. aeruginosa*.^{4,10,17,30,36,37} Rosenfeld et al. evaluated risk factors for initial *P. aeruginosa* acquisition in order to inform prevention strategies and identify high-risk populations.³⁰ They concluded that none of the modifiable risk factors evaluated, including cigarette smoke, hot tub use, breastfeeding, and newborn screening positivity, was associated with age at *P. aeruginosa* acquisition. Rosenfeld and other studies have demonstrated that minimal CFTR function is associated with earlier *P. aeruginosa* acquisition compared to those with residual CFTR function.^{23,30} Most of these studies have been conducted in the US, where the frequency of the F508del mutation is over 80%. However, due to the mutation diversity in our country, the frequency of the F508del mutation, the most common variant, is only 25%.²⁴ In the only study conducted in our country on CFTR function classification, no association was found between minimal and residual CFTR function classification and FEV1 decline.³⁸ However, we found the frequency of *P. aeruginosa* colonization was higher in those with minimal CFTR function compared to those with residual CFTR function under the age of 2 years. This causality analysis is beyond the scope of our study; however, the potential correlation between CFTR function classification in CF patients and disease severity at follow-up, including the risk of *P. aeruginosa* colonization, represents a significant research question for future investigations in our country.

The prevalence of *S. aureus* and MRSA isolation on recent respiratory culture positivity and *S. aureus* colonization were significantly higher in patients with *P. aeruginosa* colonization under 2 years of age. The relationship between *P. aeruginosa* and *S. aureus* in patients with CF is controversial in the literature. While Maselli et al. showed that *S. aureus* is a risk factor for initial *P. aeruginosa* acquisition, another study demonstrated *S. aureus* infection is significantly lower in the chronic *P. aeruginosa* group.^{16,17} In our study, although higher rates of *S. aureus* and MRSA were observed in infants with *P. aeruginosa* colonization, the limited sample size precluded robust statistical inference regarding the nature of this association. Therefore, larger studies are required to better clarify the relationship between *S. aureus* and early *P. aeruginosa* colonization.

CF registries are a valuable resource for research because they provide access to large populations; however, they also have inherent limitations due to the restricted scope of available data. By focusing on a single time point, we were unable to evaluate the long-term progression of *P. aeruginosa* colonization and its impact on pulmonary function over time. An important limitation of the present study is the lack of detailed data on eradication therapies and treatment outcomes, which precluded evaluation of the effectiveness of different therapeutic approaches in preventing chronic *P. aeruginosa* colonization. Similarly, environmental factors such as air quality and climate were not assessed, which may play a role in colonization variability across regions and centers. Future studies incorporating genetic analysis, environmental factors, and documenting treatment regimens could yield more comprehensive risk assessments. Another limitation is that our study preceded the widespread availability of CFTR modulators in Türkiye. The absence of patients receiving these therapies in our cohort may limit the generalizability of our findings to current cystic fibrosis management, as these treatments may potentially alter airway microbiology.

The relatively small number of infants with *P. aeruginosa* colonization reduced statistical power and limited the ability to perform reliable multivariable analyses, increasing the risk of type II error. Therefore, logistic regression was restricted to a small number of clinically relevant, non-treatment variables, and the absence of significant independent predictors should be interpreted with caution. Although the use of standardized Leeds criteria for colonization diagnosis enhances the study's reliability, longitudinal follow-up studies are essential to evaluate the persistence of colonization, the effectiveness of interventions, and to clarify causal relationships and risk factors.

In conclusion, this study highlights the clinical characteristics and associated factors associated with *P. aeruginosa* colonization in infants with CF in Türkiye. The higher prevalence of colonization compared to other countries underscores the need for targeted preventive strategies. Our findings suggest that minimal CFTR function may contribute to an increased risk of colonization, and the association with *S. aureus* colonization further emphasizes the complexity of early respiratory infections in CF patients. However, the lack of data on eradication therapies and treatment outcomes limits our ability to assess intervention effectiveness. Future longitudinal studies incorporating genetic, environmental, and microbiome analyses are essential to better understand the dynamics of *P. aeruginosa* acquisition and to improve early intervention strategies in CF infants.

Acknowledgements

The authors are grateful to the Cystic Fibrosis Registry of Türkiye for providing access to the data of patients and thank the individual center representatives for allowing the use of data.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee (Hacettepe University Ethics Board, date: 12 April 2007, reference number: HEK 07/16-21 and date: 5 June 2018, reference number: GO 18/473-31) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Author contribution

The authors confirm contribution to the paper as follows: Study conception and design: EO, GC; Data collection: EY, NK, VŞ, HŞŞ, DUA, HÇ, HY, ED, EDe, AB, YC, ATA, KH, MK, AÖ, NÇ, ZGGA, ÖK, HYü, ŞÖ, ET, GÇ, DC, PK, MKı; analysis and interpretation of results: GDT, SEP, DAT, BÖ, AAK, HY, GÜ, AİY, İL, GKÖ, EB, NS, PA, MH, GÖ; draft manuscript preparation: TŞE, SP, EÇ, NE, UÖ, DD. All authors reviewed the results and approved the final version of the manuscript.

Source of funding

The authors declare the study received no funding.

Conflict of interest

The authors declare that there is no conflict of interest.

REFERENCES

1. Ratjen F, Bell SC, Rowe SM, Goss CH, Quittner AL, Bush A. Cystic fibrosis. Nat Rev Dis Primers 2015; 1: 15010. <https://doi.org/10.1038/nrdp.2015.10>
2. Murray TS, Egan M, Kazmierczak BI. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Curr Opin Pediatr 2007; 19: 83-88. <https://doi.org/10.1097/MOP.0b013e3280123a5d>
3. McBennett KA, Davis PB, Konstan MW. Increasing life expectancy in cystic fibrosis: advances and challenges. Pediatr Pulmonol 2022; 57(Suppl 1): S5-S12. <https://doi.org/10.1002/ppul.25733>

4. Jackson L, Waters V. Factors influencing the acquisition and eradication of early *Pseudomonas aeruginosa* infection in cystic fibrosis. *J Cyst Fibros* 2021; 20: 8-16. <https://doi.org/10.1016/j.jcf.2020.10.008>
5. Burns JL, Gibson RL, McNamara S, et al. Longitudinal assessment of *Pseudomonas aeruginosa* in young children with cystic fibrosis. *J Infect Dis* 2001; 183: 444-452. <https://doi.org/10.1086/318075>
6. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Olinsky A, Phelan PD. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis. *Pediatr Pulmonol* 1996; 21: 267-275. [https://doi.org/10.1002/\(SICI\)1099-0496\(199605\)21:5<267::AID-PPUL1>3.0.CO;2-K](https://doi.org/10.1002/(SICI)1099-0496(199605)21:5<267::AID-PPUL1>3.0.CO;2-K)
7. Hudson VL, Wielinski CL, Regelman WE. Prognostic implications of initial oropharyngeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years. *J Pediatr* 1993; 122: 854-860. [https://doi.org/10.1016/s0022-3476\(09\)90007-5](https://doi.org/10.1016/s0022-3476(09)90007-5)
8. Savant AP, McColley SA. Cystic fibrosis year in review 2019: section 2 pulmonary disease and infections. *Pediatr Pulmonol* 2023; 58: 672-682. <https://doi.org/10.1002/ppul.25091>
9. Nixon GM, Armstrong DS, Carzino R, et al. Clinical outcome after early *Pseudomonas aeruginosa* infection in cystic fibrosis. *J Pediatr* 2001; 138: 699-704. <https://doi.org/10.1067/mpd.2001.112897>
10. Demko CA, Byard PJ, Davis PB. Gender differences in cystic fibrosis: *Pseudomonas aeruginosa* infection. *J Clin Epidemiol* 1995; 48: 1041-1049. [https://doi.org/10.1016/0895-4356\(94\)00230-n](https://doi.org/10.1016/0895-4356(94)00230-n)
11. European Cystic Fibrosis Society Patient Registry 2022 Annual Data Report. 2022. Available at: https://www.ecfs.eu/sites/default/files/Annual%20Report_2022_ECFSPR_20240603.pdf (Accessed on Jan 1, 2025).
12. Ulusal kistik fibrozis kayıt sistemi 2023 yılı verileri. 2023. Available at: <https://www.kistikfibrozisturkiye.org/wp-content/uploads/2024/11/2023-UKKS-2.pdf> (Accessed on Jan 8, 2025).
13. UK Cystic Fibrosis Registry Annual Data Report 2022. 2022. Available at: https://www.cysticfibrosis.org.uk/sites/default/files/2023-10/CFT_2022_Annual_Data_Report_FINAL_v8.pdf (Accessed on Jan 1, 2025).
14. Cystic Fibrosis Foundation Patient Registry Annual Data Report 2023. Available at: <https://www.cff.org/sites/default/files/2024-06/2023-Cystic-Fibrosis-Foundation-Patient-Registry-Highlights-Handout.pdf> (Accessed on Jan 1, 2025).
15. ECFS Patient Registry. Available at: <https://www.ecfs.eu/ecfspr/> (Accessed on Feb 20, 2020).
16. Proesmans M, Balinska-Miskiewicz W, Dupont L, et al. Evaluating the "Leeds criteria" for *Pseudomonas aeruginosa* infection in a cystic fibrosis centre. *Eur Respir J* 2006; 27: 937-943. <https://doi.org/10.1183/09031936.06.00100805>
17. Maselli JH, Sontag MK, Norris JM, MacKenzie T, Wagener JS, Accurso FJ. Risk factors for initial acquisition of *Pseudomonas aeruginosa* in children with cystic fibrosis identified by newborn screening. *Pediatr Pulmonol* 2003; 35: 257-262. <https://doi.org/10.1002/ppul.10230>
18. T.C. Sağlık Bakanlığı Türk Halk Sağlığı Kurumu. Kistik fibrozis yenidoğan tarama testi ile tanı alan hastaları izleme rehberi. 2017. Available at: https://hsgm.saglik.gov.tr/depo/birimler/cocuk_ergen_db/dokumanlar/yayinlar/Kitaplar/KF_Rehberi.pdf (Accessed on Mar 1, 2020).
19. A SAS Program for the 2000 CDC Growth Charts (ages 0 to <20 years). Available at: <https://www.cdc.gov/growth-chart-training/hcp/computer-programs/sas.html> (Accessed on Feb 25, 2022).
20. World Health Organization (WHO). WHO child growth standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. Available at: https://apps.who.int/iris/bitstream/handle/10665/43413/924154693X_eng.pdf (Accessed on Mar 12, 2021).
21. Green DM, McDougal KE, Blackman SM, et al. Mutations that permit residual CFTR function delay acquisition of multiple respiratory pathogens in CF patients. *Respir Res* 2010; 11: 140. <https://doi.org/10.1186/1465-9921-11-140>
22. McKone EF, Goss CH, Aitken ML. CFTR genotype as a predictor of prognosis in cystic fibrosis. *Chest* 2006; 130: 1441-1447. <https://doi.org/10.1378/chest.130.5.1441>
23. McKone EF, Emerson SS, Edwards KL, Aitken ML. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. *Lancet* 2003; 361: 1671-1676. [https://doi.org/10.1016/S0140-6736\(03\)13368-5](https://doi.org/10.1016/S0140-6736(03)13368-5)
24. Ulusal kistik fibrozis kayıt sistemi 2019 yıllık verileri. 2019. Available at: <https://www.kistikfibrozisturkiye.org/hasta-kayit-sistemi/#yillik-raporlar> (Accessed on Feb 22, 2022).
25. French Cystic Fibrosis Registry Annual Data Report 2019. 2021. Available at: https://www.vaincrelamuco.org/sites/default/files/french_cf_registry_2019_annual_report.pdf (Accessed on Jul 1, 2021).

26. Cystic Fibrosis Foundation Patient Registry 2019 Annual Data Report. 2020. Available at: <https://www.cff.org/sites/default/files/2021-10/2019-Patient-Registry-Annual-Data-Report.pdf> (Accessed on Dec 1, 2020).
27. French Cystic Fibrosis Registry Annual Data Report 2021. Available at: https://www.vaincrelamuco.org/sites/default/files/french_cf_registry_annual_data_report_2021.pdf (Accessed on Jan 1, 2023).
28. Martiniano SL, Elbert AA, Farrell PM, et al. Outcomes of infants born during the first 9 years of CF newborn screening in the United States: a retrospective Cystic Fibrosis Foundation Patient Registry cohort study. *Pediatr Pulmonol* 2021; 56: 3758-3767. <https://doi.org/10.1002/ppul.25658>
29. Pillarisetti N, Williamson E, Linnane B, et al. Infection, inflammation, and lung function decline in infants with cystic fibrosis. *Am J Respir Crit Care Med* 2011; 184: 75-81. <https://doi.org/10.1164/rccm.201011-1892OC>
30. Rosenfeld M, Emerson J, McNamara S, et al. Risk factors for age at initial *Pseudomonas* acquisition in the cystic fibrosis epic observational cohort. *J Cyst Fibros* 2012; 11: 446-453. <https://doi.org/10.1016/j.jcf.2012.04.003>
31. Frayman KB, Armstrong DS, Carzino R, et al. The lower airway microbiota in early cystic fibrosis lung disease: a longitudinal analysis. *Thorax* 2017; 72: 1104-1112. <https://doi.org/10.1136/thoraxjnl-2016-209279>
32. Tirouvanziam R, de Bentzmann S, Hubeau C, et al. Inflammation and infection in naive human cystic fibrosis airway grafts. *Am J Respir Cell Mol Biol* 2000; 23: 121-127. <https://doi.org/10.1165/ajrcmb.23.2.4214>
33. Guy's and St Thomas' NHS Foundation Trust. Clinical Guidelines: Care of Children Cystic Fibrosis Royal Brompton Hospital. Available at: <https://www.rbht.nhs.uk/childrencf> (Accessed on Jan 1, 2025).
34. Wainwright CE, Vidmar S, Armstrong DS, et al. Effect of bronchoalveolar lavage-directed therapy on *Pseudomonas aeruginosa* infection and structural lung injury in children with cystic fibrosis: a randomized trial. *JAMA* 2011; 306: 163-171. <https://doi.org/10.1001/jama.2011.954>
35. Manos J, Hu H, Rose BR, et al. Virulence factor expression patterns in *Pseudomonas aeruginosa* strains from infants with cystic fibrosis. *Eur J Clin Microbiol Infect Dis* 2013; 32: 1583-1592. <https://doi.org/10.1007/s10096-013-1916-7>
36. Kosorok MR, Jalaluddin M, Farrell PM, et al. Comprehensive analysis of risk factors for acquisition of *Pseudomonas aeruginosa* in young children with cystic fibrosis. *Pediatr Pulmonol* 1998; 26: 81-88. [https://doi.org/10.1002/\(sici\)1099-0496\(199808\)26:2<81::aid-ppul2>3.0.co;2-k](https://doi.org/10.1002/(sici)1099-0496(199808)26:2<81::aid-ppul2>3.0.co;2-k)
37. Wang SS, FitzSimmons SC, O'Leary LA, Rock MJ, Gwinn ML, Khoury MJ. Early diagnosis of cystic fibrosis in the newborn period and risk of *Pseudomonas aeruginosa* acquisition in the first 10 years of life: A registry-based longitudinal study. *Pediatrics* 2001; 107: 274-279. <https://doi.org/10.1542/peds.107.2.274>
38. Emirlioğlu N, Çakır B, Sertçelik A, et al. Factors associated with pulmonary function decline of patients in the cystic fibrosis registry of Turkey: a retrospective cohort study. *Pediatr Pulmonol* 2024; 59: 2956-2966. <https://doi.org/10.1002/ppul.27165>